Tetanus - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Tetanus - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 86-page report is available in PDF from $2000.

Tetanus - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Tetanus - Pipeline Review, H1 2015’, provides an overview of the Tetanus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Tetanus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Tetanus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Tetanus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Tetanus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Tetanus Overview 9
Therapeutics Development 10
Pipeline Products for Tetanus - Overview 10
Pipeline Products for Tetanus - Comparative Analysis 11
Tetanus - Therapeutics under Development by Companies 12
Tetanus - Therapeutics under Investigation by Universities/Institutes 14
Tetanus - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Tetanus - Products under Development by Companies 19
Tetanus - Products under Investigation by Universities/Institutes 21
Tetanus - Companies Involved in Therapeutics Development 22
Beijing Minhai Biotechnology Co., Ltd 22
Bharat Biotech International Limited 23
Biological E. Limited 24
Daiichi Sankyo Company, Limited 25
Green Cross Corporation 26
Indian Immunologicals Limited 27
LG Life Sciences, Ltd. 28
Novartis AG 29
Panacea Biotec Limited 30
Prometheon Pharma, LLC 31
Sanofi 32
Sanofi Pasteur SA 33
Serum Institute of India Limited 34
Sinovac Biotech Ltd. 35
Zydus Cadila Healthcare Limited 36
Tetanus - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
diphtheria + pertussis + tetanus vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
diphtheria + pertussis + tetanus vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine - Drug Profile 54 For more information open Tetanus - Pipeline Review, H1 2015.


Original Article: Tetanus - Pipeline Review, H1 2015


More From BioPortfolio on "Tetanus - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...